Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

EP. 1: Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

January 30th 2021

January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.

EP. 2: Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer

February 6th 2021

Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.

EP. 3: Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 10th 2021

Pasi A. Jänne, MD, PhD, discusses the rationale for exploring mobocertinib in EGFR exon 20–mutated non–small cell lung cancer.

EP. 4: Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities

February 10th 2021

Mary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.

EP. 5: Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

February 10th 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

EP. 6: Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

February 19th 2021

Zofia Piotrowska, MD, MHS, discusses the utility of mobocertinib in patients with non–small cell lung cancer who harbor EGFR exon 20 insertions.

EP. 7: Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC

February 25th 2021

John V. Heymach, MD, PhD, discusses the efficacy of mobocertinib in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

EP. 8: Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC

March 2nd 2021

Sarah B. Goldberg, MD, MPH, discusses the toxicity profile associated with amivantamab in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

EP. 9: Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

March 2nd 2021

Alexander Spira, MD, PhD, FACP, discusses the efficacy of mobocertinib in metastatic non–small cell lung cancer that harbors EGFR exon 20 insertion mutations.

EP. 10: Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC

March 3rd 2021

Hossein Borghaei, DO, MS, discusses unique characteristics of EGFR exon 20 insertion mutations in non–small cell lung cancer.

EP. 11: Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

March 4th 2021

John V. Heymach, MD, PhD, discusses the incidence of EGFR exon 20 insertions in lung cancer, diagnostic challenges of identifying EGFR exon 20 insertions, and data from the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer with mobocertinib and amivantamab in this patient subset.

EP. 12: Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

April 15th 2021

This publication includes a summary of data on the treatment of patients with EGFR exon 20 insertions in non–small cell lung cancer (NSCLC) and the rapidly changing landscape of HER2-targeted treatment. Thoracic oncologists, who specialize in the treatment of lung cancer, provide key insights on the current management of uncommon EGFR mutations in NSCLC and the emerging treatment landscape of targeted therapies.